MediciNova (Nasdaq:MNOV) - 주가, 뉴스 및 분석

MNOV 주식 개요

바이오 제약 회사인 메디치노바는 미국 내 미충족 의료 수요가 있는 중증 질환 치료를 위한 새로운 저분자 치료제를 개발하는 데 주력하는 회사입니다. 자세한 내용

MNOV 기본 분석
눈송이 점수
가치 평가	0/6
미래 성장	0/6
과거 실적	0/6
재무 상태	6/6
배당금	0/6

위험 분석

수익은 향후 3년간 연평균 6.1% 씩 감소할 것으로 예상됩니다.

수익이 1백만 달러 미만인 경우 ( $0 )

최근 3개월간 주가 변동폭 심해

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

MediciNova, Inc. 경쟁사

Anixa Biosciences

NasdaqCM:ANIX

US$103.0m

Adicet Bio

NasdaqGM:ACET

US$74.2m

Adverum Biotechnologies

NasdaqCM:ADVM

US$125.6m

Homology Medicines

NasdaqGS:FIXX

US$54.3m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 MediciNova
과거 주가
현재 주가	US$2.13
52주 최고치	US$2.55
52주 최저치	US$1.12
베타	0.77
11개월 변경	28.31%
3개월 변경 사항	67.72%
1년 변경 사항	15.14%
33년 변화	-33.85%
5년 변화	-70.08%
IPO 이후 변화	-80.55%

최근 뉴스 및 업데이트

Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth

Aug 28

Recent updates

Here's Why We're Not Too Worried About MediciNova's (NASDAQ:MNOV) Cash Burn Situation

Mar 18

We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth

Oct 12

MediciNova to get US patent for MN-166 to treat brain cancer

Sep 15

MediciNova's MN-166 to be part of study to treat Long COVID

Aug 16

MediciNova begins study of parenteral formulation of MN-166

Jul 22

MediciNova announces extension of BARDA contract for Ibudilast development

Jun 30

We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

Mar 19

MediciNova (NASDAQ:MNOV) Is In A Strong Position To Grow Its Business

Nov 23

MediciNova: The Pain Of A Positive Outlook

Aug 31

MediciNova stock climbs 31% on positive MN-166 data in mid-stage alcohol use disorder study

Jun 21

Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth

May 15

The MediciNova Riddle: Worth Unravelling

Apr 26

MediciNova inks $20M securities purchase agreement with 3D Investment Partners

Jan 12

MediciNova nabs new U.S. patent for ibudilast in multiple sclerosis

Dec 29

MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans

Dec 29

주주 수익률

	MNOV	US Biotechs	US 마켓
7D	16.4%	2.5%	2.2%
1Y	15.1%	16.1%	31.6%

수익률 대 산업: MNOV 지난 1년 동안 16.1 %를 반환한 US Biotechs 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: MNOV 지난 1년 동안 31.6 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is MNOV's price volatile compared to industry and market?
MNOV volatility
MNOV Average Weekly Movement	19.1%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

안정적인 주가: MNOV 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: MNOV 의 주간 변동성은 지난 1년 동안 11% 에서 19% 로 증가했습니다.

회사 소개

설립	직원	CEO	웹사이트
2000	13	Yuichi Iwaki	www.medicinova.com

바이오 제약 회사인 메디치노바는 미국에서 미충족 의료 수요가 있는 중증 질환 치료를 위한 새로운 저분자 치료제를 개발하는 데 주력하고 있습니다. 회사는 일차 및 이차 진행성 다발성 경화증, 근위축성 측삭 경화증, 화학 요법으로 인한 말초 신경 병증, 퇴행성 경추 척수증, 교모세포종, 물질 의존 및 중독과 같은 신경 및 기타 장애를 치료하고 급성 호흡곤란 증후군 및 장기 COVID 예방을 위한 경구 항염증 및 신경 보호제인 MN-166(이부딜라스트)을 개발 중입니다. 이 회사의 제품 파이프라인에는 천식 급성 악화 치료를 위한 선택적 베타-2 아드레날린 수용체 작용제인 MN-221(베도라드린), 비알코올성 지방간 질환과 특발성 폐섬유증을 포함한 섬유성 및 기타 질환 치료를 위한 경구 생체 이용성 저분자 화합물인 MN-001(티펠루카스트), 고형암 치료를 위한 투불린 결합제인 MN-029(데니불린) 등도 포함되어 있습니다.

MediciNova, Inc. 기본 사항 요약

MediciNova 의 수익과 매출은 시가총액과 어떻게 비교하나요?
MNOV 기본 통계
시가총액	US$104.47m
수익(TTM)	-US$10.29m
수익(TTM)	n/a

0.0x

P/S 비율

-10.1x

P/E 비율

MNOV 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
MNOV 손익 계산서(TTM)
수익	US$0
수익 비용	US$0
총 이익	US$0
기타 비용	US$10.29m
수익	-US$10.29m

최근 보고된 수익

Sep 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-0.21
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	0%

MNOV 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

MNOV 주식 개요

위험 분석

MediciNova, Inc. 경쟁사

NasdaqCM:ANIX

US$103.0m

NasdaqGM:ACET

US$74.2m

NasdaqCM:ADVM

US$125.6m

NasdaqGS:FIXX

US$54.3m

가격 내역 및 성능

최근 뉴스 및 업데이트

Medicinova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver

MediciNova, Inc. to Report Q3, 2024 Results on Nov 14, 2024

MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)

MediciNova, Inc. Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition

Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth

MediciNova, Inc. to Report Q2, 2024 Results on Aug 09, 2024

Recent updates

Medicinova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver

MediciNova, Inc. to Report Q3, 2024 Results on Nov 14, 2024

MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)

MediciNova, Inc. Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition

Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth

MediciNova, Inc. to Report Q2, 2024 Results on Aug 09, 2024

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer

MediciNova, Inc. Announces Data from Phase 1B/2A Clinical Trial of Mn-166 (Ibudilast) in Glioblastoma Patients At the American Society of Clinical Oncology (Asco) Annual Meeting 2024

MediciNova, Inc. Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome

MediciNova, Inc. Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)

MediciNova, Inc., Annual General Meeting, Jun 11, 2024

We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

MediciNova, Inc. to Report Q1, 2024 Results on May 10, 2024

MediciNova, Inc. Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan

Medicinova Announces New Data and Results of Mn-166 (Ibudilast) in Chlorine Gas-Induced Acute Lung Injury Presented At the 63Rd Annual Meeting of the Society of Toxicology

Price target increased by 69% to US$27.00

MediciNova, Inc. to Report Fiscal Year 2023 Results on Feb 14, 2024

MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China

MediciNova, Inc. Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-Induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology

MediciNova, Inc. Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe

MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans

MediciNova, Inc. to Report Q3, 2023 Results on Nov 10, 2023

Price target decreased by 41% to US$16.00

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology

MediciNova, Inc. Receives A Notice of Intention to Grant for A New Patent Covering MN-166 (Ibudilast) for the Treatment of Macular Injury in Europe

Less than half of directors are independent

We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

MediciNova, Inc. Announces Presentation of Results from the Phase 2B Trial of Mn-166 (Ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting

Here's Why We're Not Too Worried About MediciNova's (NASDAQ:MNOV) Cash Burn Situation

MediciNova Announces Health Canada Grants Authorization to Commence Multi-Arm Phase 2/3 Clinical Trial to Evaluate MN-166 (ibudilast) in Long COVID

MediciNova, Inc. Announces Completion of Enrollment in the Phase 2b Clinical Trial of MN 166 (ibudilast) in Alcohol Use Disorder

MediciNova, Inc. Announces Completion of Enrollment in the Phase 2 Clinical Trial Evaluating MN-166 (ibudilast) for Treatment of Recurrent and Newly Diagnosed Glioblastoma

MediciNova Receives Notice of Allowance for A New Patent Covering Mn-001 and Mn-002 for the Treatment of Scleroderma and Systemic Sclerosis in Canada

MediciNova, Inc. Receives Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Brazil

MediciNova, Inc. Completes Phase I Clinical Trial to Evaluate MN-166 10 MG Intravenous Infusion in Healthy Volunteers

MediciNova, Inc. Announces Additional Positive Results Regarding the Effects of MN-001 (tipelukast) on Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Presents at IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation

Price target decreased to US$13.00

We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth

MediciNova, Inc. to Report Q3, 2022 Results on Nov 11, 2022

MediciNova to get US patent for MN-166 to treat brain cancer

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Canada

MediciNova's MN-166 to be part of study to treat Long COVID

First half 2022 earnings released

MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in Korea

MediciNova, Inc Announces Initiation of a Phase 2 Trial of MN-001 (tipelukast) in NAFLD with Type 2 Diabetes Mellitus and Hypertriglyceridemia

MediciNova, Inc. to Report Q2, 2022 Results on Aug 12, 2022

MediciNova, Inc. Initiates Clinical Evaluation of a New Parenteral Formulation of MN-166 (ibudilast)

MediciNova begins study of parenteral formulation of MN-166

MediciNova announces extension of BARDA contract for Ibudilast development

MediciNova, Inc. Announces Executive Changes

MediciNova, Inc. Announces Positive Top-Line Results from Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome

Price target decreased to US$13.00

MediciNova, Inc. to Report Q1, 2022 Results on May 13, 2022

MediciNova, Inc. Announces Publication of MN-166 (ibudilast) Data regarding Prevention of Metastasis in Uveal Melanoma in Molecular Cancer Research

MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome

MediciNova, Inc. Announces Plans for A Phase 2 Trial of Mn-001 (Tipelukast) in Nafld with Type 2 Diabetes Mellitus and Hypertriglyceridemia

MediciNova, Inc. Announces Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Alcoholism: Clinical and Experimental Research

We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

MediciNova, Inc. announces MN-166 (ibudilast) Identified as Promising Pharmacotherapy for Alcohol Use Disorder in Drugs

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for Hepatic Ballooning in Canada